Spectromics Company

Spectromics develops a diagnostic system that helps to guide antibiotic treatment. It provides a fast, simple, accurate, and cost-effective test for bacterial infections that identifies anti-microbial susceptibility/resistance during a patient appointment. Then includes guidance on the most effective treatment for a particular pathogen and which drug to prescribe. Spectromics focuses its internal activities on technology development whilst engaging with partners who bring complementary expertise in instrument development/production and cartridge manufacture. The novel and proprietary technology are based on spectrometric monitoring of phenotypic change that occurs in reactions between the sample and a candidate antibiotic panel.

Founded Date: 2014
Last Funding Type: Series A
Headquarters: Manchester, United Kingdom
Investors Number: 2
Employee Number: 1-10
Industry: P4 medicine
Estimated Revenue: < £780 000
Last Funding Date: 06-29-2015
Funding Status: Early Stage Venture